BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duchow A, Chien C, Paul F, Bellmann-Strobl J. Emerging drugs for the treatment of neuromyelitis optica. Expert Opin Emerg Drugs 2020;25:285-97. [PMID: 32731771 DOI: 10.1080/14728214.2020.1803828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ding J, Cai Y, Deng Y, Jiang X, Gao M, Lin Y, Zhao N, Wang Z, Yu H, Lv W, Zhang Y, Hao Y, Guan Y. Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study. Front Neurol 2021;12:596791. [PMID: 33868140 DOI: 10.3389/fneur.2021.596791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ayzenberg I, Kleiter I. [Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease]. Nervenarzt 2021;92:334-48. [PMID: 33783551 DOI: 10.1007/s00115-021-01090-4] [Reference Citation Analysis]
3 Ding J, Jiang X, Cai Y, Pan S, Deng Y, Gao M, Lin Y, Zhao N, Wang Z, Yu H, Qiu H, Jin Y, Xue J, Guo Q, Ni L, Zhang Y, Hao Y, Guan Y. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study. CNS Neurosci Ther. [DOI: 10.1111/cns.13904] [Reference Citation Analysis]
4 Asseyer S, Masuda H, Mori M, Bellmann-Strobl J, Ruprecht K, Siebert N, Cooper G, Chien C, Duchow A, Schließeit J, Liu J, Sugimoto K, Uzawa A, Ohtani R, Paul F, Brandt AU, Kuwabara S, Zimmermann HG. AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 2021;7:20552173211006862. [PMID: 34017610 DOI: 10.1177/20552173211006862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Schmetzer O, Lakin E, Roediger B, Duchow A, Asseyer S, Paul F, Siebert N. Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Front Neurol 2021;12:635419. [PMID: 33776892 DOI: 10.3389/fneur.2021.635419] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ma J, Yu H, Wang H, Zhang X, Feng K. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. J Neuroimmunol 2021;363:577790. [PMID: 34959021 DOI: 10.1016/j.jneuroim.2021.577790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Duchow A, Bellmann-strobl J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative Disease Management 2021;11:49-59. [DOI: 10.2217/nmt-2020-0046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord 2020;46:102538. [PMID: 33059216 DOI: 10.1016/j.msard.2020.102538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]